Arch Biopartners Inc.
ARCH.V
TSX
| Weiss Ratings | ARCH.V - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | ARCH.V - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Weak | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | ARCH.V - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.65 | |||
| Price History | ARCH.V - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 0.42% | |||
| 30-Day Total Return | 34.46% | |||
| 60-Day Total Return | 51.59% | |||
| 90-Day Total Return | 65.28% | |||
| Year to Date Total Return | 64.14% | |||
| 1-Year Total Return | 13.33% | |||
| 2-Year Total Return | -40.65% | |||
| 3-Year Total Return | 78.95% | |||
| 5-Year Total Return | 85.94% | |||
| 52-Week High % Change | -9.77% | |||
| 52-Week Low % Change | 138.14% | |||
| Price | ARCH.V - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $2.56 | |||
| 52-Week Low Price | $0.97 | |||
| 52-Week Low Price (Date) | Nov 03, 2023 | |||
| 52-Week High Price (Date) | Mar 18, 2024 | |||
| Valuation | ARCH.V - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 108.74M | |||
| Enterprise Value | 112.32M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.02 | |||
| Earnings Per Share Growth | -60.24% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 109.68 | |||
| Price/Book (Q) | -34.54 | |||
| Enterprise Value/Revenue (TTM) | 81.09 | |||
| Price | $2.38 | |||
| Enterprise Value/EBITDA (TTM) | -- | |||
| Enterprise Value/EBIT | -103.43 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | ARCH.V - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 62.47M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | ARCH.V - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 647-428-7031 | |||
| Address | 27 Street Clair Avenue East Toronto, ON M4T 2M5 | |||
| Website | www.archbiopartners.com | |||
| Country | Canada | |||
| Year Founded | -- | |||
| Profitability | ARCH.V - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -78.40% | |||
| Profit Margin | -106.09% | |||
| Management Effectiveness | ARCH.V - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -131.43% | |||
| Return on Equity | -- | |||
| Income Statement | ARCH.V - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 1.36M | |||
| Total Revenue (TTM) | 1.36M | |||
| Revenue Per Share | $0.02 | |||
| Gross Profit (TTM) | 26.80K | |||
| EBITDA (TTM) | -- | |||
| EBIT (TTM) | -1.06M | |||
| Net Income (TTM) | -1.44M | |||
| Net Income Avl. to Common (TTM) | -1.44M | |||
| Total Revenue Growth (Q YOY) | -31.60% | |||
| Earnings Growth (Q YOY) | 63.79% | |||
| EPS Diluted (TTM) | -0.02 | |||
| EPS Diluted Growth (Q YOY) | 63.92% | |||
| Balance Sheet | ARCH.V - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 229.20K | |||
| Cash Per Share (Q) | $0.00 | |||
| Total Current Assets (Q) | 482.00K | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -4.33M | |||
| Current Ratio (Q) | 0.109 | |||
| Book Value Per Share (Q) | -$0.07 | |||
| Total Assets (Q) | 482.00K | |||
| Total Current Liabilities (Q) | 4.43M | |||
| Total Debt (Q) | 3.81M | |||
| Total Liabilities (Q) | 4.81M | |||
| Total Common Equity (Q) | -4.33M | |||
| Cash Flow | ARCH.V - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -1.00M | |||
| Cash from Financing (TTM) | 1.43M | |||
| Net Change in Cash (TTM) | 107.80K | |||
| Levered Free Cash Flow (TTM) | 139.30K | |||
| Cash from Operations (TTM) | -1.32M | |||
